SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending after securing a major contract with NASA to deliver lunar landers by 2028, sparking intense community debate between bulls betting on a rebound and skeptics wary of dilution and short-term volatility. Investors are closely monitoring the stock's price action as it attempts to break through recent resistance following a period of heavy downward pressure.

Penguin Solutions, Inc. engages in designing, building, and managing enterprise solutions. It operates through the following segments: Advanced Computing, Integrated Memory, and Optimized LED. The Advanced Computing segment offers platform solutions and services for artificial intelligence, high-performance computing, machine learning, advanced modeling, and the internet of things. The Integrated Memory refers to integrated memory solutions through the design and development. The Optimized LED segment comprises a broad portfolio of application-optimized LEDs. The company was founded in 1988 and is headquartered in Fremont, CA.

Penguin Solutions Inc.

Penguin Solutions is trending as investors react to a strong quarterly earnings report featuring a revenue beat and upwardly revised guidance driven by robust AI infrastructure and integrated memory demand. The community is actively debating the stock's future, weighing significant short interest and potential share dilution against its strategic positioning as a specialized NVIDIA AI factory partner.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing intense volatility as investors weigh robust long-term demand for AI-driven memory infrastructure against sector-wide jitters triggered by regional market weakness and broader semiconductor sell-offs. Community sentiment is deeply divided between those betting on a major reversal due to strong fundamental backlogs and those fearing a potential bubble burst as institutional capital rotates into other sectors.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp is currently at the center of intense volatility as investors debate whether the recent sharp pullback is a structural breakdown or an opportunity to buy the dip. The community remains deeply divided, with bearish traders highlighting macroeconomic concerns and cooling AI momentum, while bulls continue to focus on long-term data center demand and potential stock split catalysts.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is gaining strong momentum as investors anticipate upcoming maintenance data for its lead GLP-1/GIP obesity drug, fueling intense speculation regarding a potential buyout or strategic partnership. The community is actively discussing a technical breakout and the stock's role as a major competitor in the obesity market, with many bulls highlighting high short interest as a potential catalyst for further gains.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is gaining significant community attention as a critical infrastructure provider for real-world asset data, with recent integrations across major prediction markets and partnerships with top-tier financial institutions. Investors are actively discussing the network's role in the AI and DeFi sectors, frequently highlighting its utility as a high-speed data source for institutional-grade financial applications.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

The Dow Jones Industrial Average is capturing significant community attention as it navigates record-setting levels and volatile market rotations. Investors are intensely debating the sustainability of current valuations, rotating between established tech names and cyclical sectors while monitoring ongoing geopolitical developments.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

VanEck Gold Miners ETF (GDX) is trending as traders analyze a potential bottom following significant volatility, with many monitoring critical support zones as institutional interest in gold remains high. The community is actively debating the impact of the Fed's potential interest rate trajectory and macroeconomic headwinds on miners' performance in this current commodity cycle.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is experiencing extreme volatility as investors react to a significant share buyback program and legal news, while the community remains deeply divided between those viewing the current valuation as a deep-value opportunity and others labeling it a perennial value trap. Sentiment is heavily influenced by ongoing concerns over geopolitical risk, regulatory pressures in both China and the U.S., and active institutional rotation, leading to a high-volume tug-of-war between speculative buyers and entrenched bears.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is currently facing intense volatility as the community remains deeply divided between bulls citing long-term infrastructure potential and bears anticipating a move toward new lows. The stock continues to be heavily influenced by Bitcoin's price fluctuations and broader regulatory news, with significant debate surrounding whether recent sell-offs represent a bottoming process or the beginning of further downside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$BCTX It&#39;s interesting that not much people have this on their watch list. With a float of 8-12m shares, any good news will fire the stock price into the atmosphere. It dropped more than 80% in a year. Watch it to go to 40x the price it has now as soon as the 144th event drops. It&#39;s like investing in $SLS but at 0,15$

The Legendary Mayor

Justin

Tim H

Richard

Adam Roberts

StockTwits For Android 

BriaCell Therapeutics Corp

SELLAS Life Sciences Group Inc

 It's interesting that not much people have this on their watch list. With a float of 8-12m shares, any good news will fire the stock price into the atmosphere. It dropped more than 80% in a year. Watch it to go to 40x the price it has now as soon as the 144th event drops. It's like investing in 

Markus

@StormHunter89 I like the way you think Hunter.  $BCTX should be on all $SLS profit takers&#39; radars.  Thanks for the heads-up and keep reminding us.  Some of my friends here haven&#39;t joined the $BCTX train yet so keep on &#39;em.   
 
Cheers!

StockTwits Web

 profit takers' radars.  Thanks for the heads-up and keep reminding us.  Some of my friends here haven't joined the 

@StormHunter89 dilution risk? I would grab some @ $3

StockTwits for iOS

Sihttegroftnod

@Sihttegroftnod Dilution ist always a risk, but when you look at the chart, what would a for example 30% dilution do to a 140$ stock price lol from 3 bucks upwards?

 Dilution ist always a risk, but when you look at the chart, what would a for example 30% dilution do to a 140$ stock price lol from 3 bucks upwards?

@StormHunter89 right, but if they split or heavily dilute for funding it may not be a good time, yet? I’ve been watching it for a week wanting to enter @3. I have BOT done my DD yet. Just asking. What makes it $140? Got some quick good DD you can point me too, please?

 right, but if they split or heavily dilute for funding it may not be a good time, yet? I’ve been watching it for a week wanting to enter @3. I have BOT done my DD yet. Just asking. What makes it $140? Got some quick good DD you can point me too, please?

@Sihttegroftnod Cancer Med, world wide study, goes longar than it should. 144th death hasn&#39;t occurred. But it can any time, FDA fast track, stock price is at cash price, but company has a lot of study and meds in the going. Market cap is a 30m. That&#39;s a joke for a phase 3 company. Any news will have fight the buyers around 8m shares. Look at IBRX for example. They have a share price 8+ and have nearly 900m shares. What do you think will happen when a positive phase 3 drops out of the sky and we have a stock price of 4 bucks. According to calculations the worst positive outcome is 8x-15x. If this gets a 1bil BO, we have a 140$ stock price. So invest 1k and get 30k invest 10k  and get 300k. Good deal huh?

 Cancer Med, world wide study, goes longar than it should. 144th death hasn't occurred. But it can any time, FDA fast track, stock price is at cash price, but company has a lot of study and meds in the going. Market cap is a 30m. That's a joke for a phase 3 company. Any news will have fight the buyers around 8m shares. Look at IBRX for example. They have a share price 8+ and have nearly 900m shares. What do you think will happen when a positive phase 3 drops out of the sky and we have a stock price of 4 bucks. According to calculations the worst positive outcome is 8x-15x. If this gets a 1bil BO, we have a 140$ stock price. So invest 1k and get 30k invest 10k  and get 300k. Good deal huh?

@StormHunter89 nice thanks for the info. I bought more SLS today, actually pushing me into margin. I’m about 130% SLS so I can’t do much right now anyway. 🤣 but I’m on watch! Thanks!

 nice thanks for the info. I bought more SLS today, actually pushing me into margin. I’m about 130% SLS so I can’t do much right now anyway. 🤣 but I’m on watch! Thanks!

@Sihttegroftnod You&#39;re welcome I&#39;m heavy in SLS too 🤣 that&#39;s why I&#39;m so positive for this. When both fire I&#39;ll be frikin rich 🤣

 You're welcome I'm heavy in SLS too 🤣 that's why I'm so positive for this. When both fire I'll be frikin rich 🤣

@StormHunter89  I’m in this with 115K at $30  and still not letting go I talk to people who are in it at $300  I have a feeling there is a pile of people stuck in this from past delusion  I almost let go of it down 30k when they where in proses of raising 30 million about almost a year ago that when there where about 3 million shares at the time.  But dint just to make it a little harder for a scum bag obnoxious  short seller.   I figured I’d help keep it propped up a bit With what I could with the shares I have and went kamikaze  😆   Ive tried to get in successful  phase 3 before and never was able to because the price moves so fast upwards it’s crazy.   I see myself recovering and still will probably make a nice chunk of money but so wish I was getting in here.  ￼￼￼

  I’m in this with 115K at $30  and still not letting go I talk to people who are in it at $300  I have a feeling there is a pile of people stuck in this from past delusion  I almost let go of it down 30k when they where in proses of raising 30 million about almost a year ago that when there where about 3 million shares at the time.  But dint just to make it a little harder for a scum bag obnoxious  short seller.   I figured I’d help keep it propped up a bit With what I could with the shares I have and went kamikaze  😆   Ive tried to get in successful  phase 3 before and never was able to because the price moves so fast upwards it’s crazy.   I see myself recovering and still will probably make a nice chunk of money but so wish I was getting in here.  ￼￼￼

@JediGreen Ouch that must hurt, but that&#39;s how biotech is. Lower your buy in is often all you can do 😅

 Ouch that must hurt, but that's how biotech is. Lower your buy in is often all you can do 😅

@StormHunter89  This is my personal opinion.  But if we do get lucky and a buy where to happen.  I personally see this company being bought out for no less than 7 billion.  From what I understand is the standard of care drug used today  for this type of sickness was bought out  for 21 billion I think like in the year 2023 dint look into what other assets they had.  But yeah big numbers.   This is all on top of head,  so you would have to look into it.   ￼￼￼

  This is my personal opinion.  But if we do get lucky and a buy where to happen.  I personally see this company being bought out for no less than 7 billion.  From what I understand is the standard of care drug used today  for this type of sickness was bought out  for 21 billion I think like in the year 2023 dint look into what other assets they had.  But yeah big numbers.   This is all on top of head,  so you would have to look into it.   ￼￼￼

@StormHunter89 In a landmark 2020 deal, Gilead Sciences acquired Immunomedics for $21 billion. The buyout valued Immunomedics at $88 per share in cash and provided Gilead with global rights to Trodelvy, a promising cancer antibody-drug conjugate (ADC).     This is from AI

 In a landmark 2020 deal, Gilead Sciences acquired Immunomedics for $21 billion. The buyout valued Immunomedics at $88 per share in cash and provided Gilead with global rights to Trodelvy, a promising cancer antibody-drug conjugate (ADC).     This is from AI

@JediGreen That would be 800 bucks a share. I&#39;m getting sweaty hands 🤣

 That would be 800 bucks a share. I'm getting sweaty hands 🤣